Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving Dasatinib” (2012–2015) and “Quality of Life...

Full description

Saved in:

Bibliographic Details
Main Authors:	TI Ionova, NB Bulieva, OYu Vinogradova, TA Gritsenko, LK Kozlova, GB Kuchma, EG Lomaia, ER Machyulaitene, TP Nikitina, NV Novitskaya, AYu Rodionova, EI Usacheva, TV Shneider
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-04-01
Series:	Клиническая онкогематология
Subjects:	quality of life chronic myeloid leukemia dasatinib therapy effectiveness therapy safety routine clinical practice
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/03/10.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up
by: T. I. Ionova, et al.
Published: (2015-10-01)

Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells
by: Jin-Nyoung Ho, et al.
Published: (2024-11-01)

Integrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan’s Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats
by: Alhazzani K, et al.
Published: (2024-12-01)

Dasatinib and Quercetin Combination Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy
by: Antonio Battaglia-Vieni, et al.
Published: (2025-05-01)

Combination of dasatinib and quercetin promotes osteogenic differentiation and stemness maintenance of hPDLSCs via YAP/TAZ
by: Yunge Qiu, et al.
Published: (2025-12-01)

Gelatinous Marrow Transformation in Chronic Myeloid Leukemia Post-Dasatinib Treatment: A Case Report with Review of Literature
by: Gayathri Kini, et al.

Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia
by: Cheng F, et al.
Published: (2025-05-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Exercise hemodynamic evaluation in the management of dasatinib-related pulmonary arterial hypertension: a case report
by: Shuhei Yamashita, et al.
Published: (2025-05-01)

Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation
by: Mahipal Reddy Donthi, et al.
Published: (2023-02-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Azienda Ospedaliera "Carlo Poma", Mantova
by: Francesco Frattini, et al.
Published: (2014-08-01)

Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy
by: KM Abdulkadyrov, et al.
Published: (2016-01-01)

Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia
by: Totka Dodevska
Published: (2025-07-01)

Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)
by: EYu Chelysheva, et al.
Published: (2019-03-01)

Targeted delivery of liposomal senolytics to alleviate cellular senescence-induced bone loss
by: Rong Li, et al.
Published: (2025-07-01)

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
by: Julia Krushkal, et al.
Published: (2024-12-01)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Target protein identification in live cells and organisms with a non-diffusive proximity tagging system
by: Yingjie Sun, et al.
Published: (2024-12-01)

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene
by: Ewelina Testoni, et al.
Published: (2016-01-01)

Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)

Aspergillosis in patients with hematological malignancies
by: N. B. Bulieva
Published: (2014-07-01)

In search for effective methods of routine formation
by: Kandora Marcin
Published: (2017-05-01)

The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity
by: Ali N. A. Hmedat, et al.
Published: (2025-06-01)

Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01)

Developing a European Psychotherapy Consortium (EPoC): Towards Adopting a Single-Item Self-Report Outcome Measure Across European Countries
by: Miguel M. Gonçalves, et al.
Published: (2024-09-01)

Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells
by: Hiroshi Kazama, et al.
Published: (2025-01-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Penjara sebagai Lembaga Pendisiplinan: Sejarah Kehidupan Sehari-Hari di Penjara Perempuan Malang, 1984-2004
by: Ian Iradatillah Muhtarom, et al.
Published: (2025-08-01)

Poboljšanje profila oslobađanja lijeka mehanokemijskom pripravom amorfnih čvrstih disperzija
by: Paola Grobenski, et al.
Published: (2024-12-01)

Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
by: Ekaterina Chelysheva, et al.
Published: (2018-05-01)

ESTIMATION OF COMPETITIVE ACTIVITY IN SYNCHRONIZED SWIMMING
by: L.M. Shul'ga, et al.
Published: (2013-02-01)

WHY IS IT NECESSARY TO STUDY THE PEDAGOGICAL ROUTINE?
by: Alevtina S. Robotova
Published: (2016-12-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

TEMPO-RHYTHMIC ABILITIES OF THE GYMNASTS AS A FACTOR DETERMINING THE DIFFICULTY OF COMPOSITE SOLUTION OF COMPETITIVE ROUTINE IN GROUP ROUTINES DEPENDING ON THE CHOICE OF MUSICAL ACCOMPANIMENT
by: Aleksandra Suprun, et al.
Published: (2019-12-01)

Using primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adultsResearch in context
by: Xinyi Zhang, et al.
Published: (2025-01-01)